Centessa Pharmaceuticals plc
CNTA
$16.08
-$0.73-4.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | -- | 6.85M | 6.85M | 6.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | -- | 6.85M | 6.85M | 6.85M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.00M | -- | 6.85M | 6.85M | 6.85M |
| SG&A Expenses | 49.71M | 50.81M | 49.42M | 48.94M | 51.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.74M | 201.06M | 168.51M | 162.31M | 165.35M |
| Operating Income | -195.74M | -201.06M | -161.65M | -155.46M | -158.50M |
| Income Before Tax | -220.09M | -232.91M | -158.33M | -157.84M | -163.67M |
| Income Tax Expenses | 3.76M | 2.84M | 2.94M | -496.00K | -25.25M |
| Earnings from Continuing Operations | -223.85 | -235.76 | -161.27 | -157.35 | -138.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -223.85M | -235.76M | -161.27M | -157.35M | -138.42M |
| EBIT | -195.74M | -201.06M | -161.65M | -155.46M | -158.50M |
| EBITDA | -195.27M | -200.56M | -161.15M | -154.95M | -157.98M |
| EPS Basic | -1.81 | -1.99 | -1.52 | -1.56 | -1.42 |
| Normalized Basic EPS | -0.95 | -1.07 | -0.92 | -0.97 | -1.03 |
| EPS Diluted | -1.81 | -1.99 | -1.52 | -1.56 | -1.42 |
| Normalized Diluted EPS | -0.95 | -1.07 | -0.92 | -0.97 | -1.03 |
| Average Basic Shares Outstanding | 490.83M | 457.68M | 423.55M | 403.95M | 389.62M |
| Average Diluted Shares Outstanding | 490.83M | 457.68M | 423.55M | 403.95M | 389.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |